CytoDel Overview
- Founded
-
2012

- Status
-
Private
- Employees
-
6

- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$277K
- Investors
-
3
CytoDel General Information
Description
Provider of a biotechnology platform intended to produce recombinant derivatives of botulinum neurotoxin (BoNT). The company's platform manipulates the BoNT molecule into a drug delivery vehicle that can deliver therapeutic molecules to the inside of neurons with important implications, enabling medical researchers to develop drugs and facilitate the treatment of nervous system disorders, chronic pain, and neurodegenerative diseases.
Contact Information
Website
www.cytodel.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 423 West 127th Street
- New York, NY 10027
- United States
+1 (501) 000-0000
CytoDel Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
6. Grant | 01-Mar-2022 | $277K | 00.00 | Completed | Pre-Clinical Trials | |
5. Accelerator/Incubator | 00.00 | Completed | Pre-Clinical Trials | |||
4. Later Stage VC (Series A) | 16-Jan-2018 | 00.00 | 00.00 | 000.00 | Completed | Pre-Clinical Trials |
3. Grant | 01-Jul-2017 | 000.00 | Completed | Pre-Clinical Trials | ||
2. Grant | 01-Jan-2014 | $224K | Completed | Pre-Clinical Trials | ||
1. Accelerator/Incubator | 13-Dec-2013 | Completed | Pre-Clinical Trials |
CytoDel Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A-1 | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.00 | |
Series A-2 | 000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00 |
CytoDel Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Provider of a biotechnology platform intended to produce recombinant derivatives of botulinum neurotoxin (BoNT). The com
Drug Discovery
New York, NY
6
As of 2023
00.00
0000000000
00.00
CytoDel Competitors (5)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Biogen | Formerly VC-backed | Cambridge, MA | 0000 | 000.00 | 000000&0 | |
000000 | Corporation | North Chicago, IL | 00000 | 00.000 | 00000000000 | 00.000 |
000 00000 | Corporation | Indianapolis, IN | 00000 | 000000 - 000 | ||
00000 | Formerly PE-Backed | Thousand Oaks, CA | 00000 | 00.000 | 000000000000 | 00.000 |
0000 000000 | Corporation | Frankfurt, Germany | 0000 |
CytoDel Executive Team (3)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Philip Band Ph.D | Co-Founder, Chief Executive Officer & Board Member | ||
Konstantin Ichtchenko Ph.D | Co-Founder, CSO and Founding Scientist |
CytoDel Board Members (6)
Name | Representing | Role | Since |
---|---|---|---|
André Gudger | CytoDel | Board Member | 000 0000 |
Dennis Huang | CytoDel | Board Member | 000 0000 |
Lawrence Remmel JD | Self | Board Member | 000 0000 |
Margery Fischbein | Self | Board Member | 000 0000 |
Philip Band Ph.D | CytoDel | Co-Founder, Chief Executive Officer & Board Member | 000 0000 |
CytoDel Signals
CytoDel Investors (3)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
NYU Entrepreneurial Institute | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | |
National Institutes of Health | Government | 000 0000 | 000000 0 | ||
U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 |